Page 1

Contacts : Nick Childs , IQVIA Investor Relations ( nicholas.childs@iqvia.com ) +1.973.316.3828 Tor Constantino , IQVIA Media Relations ( tor.constantino@iqvia.com ) +1.484.567.6732 IQVIA IQVIA Reports Second - Quarter 2021 Results and Raises Full - Year 2021 Guidance Revenue of $ 3,438 million for the second quarter grew 36.4 percent year - over - year GAAP Net Income of $ 175 million for the second quarter increased from $ ( 23 ) million in 2020 Adjusted EBITDA of $ 722 million for the second quarter increased from $ 483 million in 2020 GAAP Diluted Earnings per Share of $ 0.90 for the second quarter increased from $ ( 0.12 ) in 2020 Adjusted Diluted Earnings per Share of $ 2.13 for the second quarter increased from $ 1.18 in 2020 R & D Solutions contracted backlog of $ 23.9 billion grew 16.7 percent year - over - year ; next twelve months revenue from backlog increased to $ 6.6 billion , up 19.6 percent year - over - year Full - year 2021 guidance raised for revenue , Adjusted EBITDA , and Adjusted Diluted EPS RESEARCH TRIANGLE PARK , N.C. July 27 , 2021 - IQVIA Holdings Inc. ( “ IQVIA ” ) ( NYSE : IQV ) , a leading global provider of advanced analytics , technology solutions , and clinical research services to the life sciences industry , today reported financial results for the quarter ended June 30 , 2021 . Second - Quarter 2021 Operating Results Revenue for the second quarter of $ 3,438 million increased 36.4 percent on a reported basis and 33.2 percent at constant currency compared to the second quarter of 2020. Technology & Analytics Solutions ( TAS ) revenue of $ 1,353 million grew 22.0 percent on a reported basis and 17.9 percent at constant currency . Research & Development Solutions ( R & DS ) revenue of $ 1,891 illion grew 53.1 percent on a reported basis and 50.7 percent at constant currency . Excluding the impact of pass throughs , R & DS revenue increased 44.6 percent year - over - year on a reported basis . Contract Sales & Medical Solutions ( CSMS ) revenue of $ 194 million grew 9.6 percent on a reported basis and 7.3 percent at constant currency . R & DS contracted backlog , including reimbursed expenses , grew 16.7 percent year - over - year to $ 23.9 billion as of June 30 , 2021. The company expects approximately $ 6.6 billion of this backlog to convert to revenue in the next twelve months , representing growth of 19.6 percent compared to June 30 , 2020. The second - quarter contracted net book - to - bill ratio was 1.34x including reimbursed expenses and 1.37x excluding reimbursed expenses . For the last twelve months ended June 30 , 2021 , the contracted net book - to - bill ratio was 1.45x including reimbursed expenses and 1.40x excluding reimbursed expenses . " We exceeded our targets cross all key financial metrics and delivered exceptional organic revenue growth as well as robust earnings and free cash flow , " said Ari Bousbib , chairman and CEO of IQVIA . " Both the TAS and R & DS segments sustained their momentum , reporting strong double - digit organic growth . The outlook for the life sciences industry remains healthy and we expect continued strength in demand for our differentiated clinical and commercial offerings . As a result of our performance and the sustained market momentum , we are once again raising our full year 2021 financial guidance . " Second - quarter GAAP net income was $ 175 million versus $ ( 23 ) million in 2020 , and GAAP diluted earnings per share was $ 0.90 versus $ ( 0.12 ) in 2020. Adjusted Net Income was $ 416 million and Adjusted Diluted Earnings per 1